These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 35349833)

  • 41. Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
    Simão F; Ustunkaya T; Clermont AC; Feener EP
    Blood; 2017 Apr; 129(16):2280-2290. PubMed ID: 28130211
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety of Intravenous Thrombolysis among Stroke Patients Taking New Oral Anticoagulants--Case Series and Systematic Review of Reported Cases.
    Shahjouei S; Tsivgoulis G; Bavarsad Shahripour R; Jones GM; Alexandrov AV; Zand R
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2685-93. PubMed ID: 26542821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator.
    Shimada Y; Shimura H; Tanaka R; Yamashiro K; Koike M; Uchiyama Y; Urabe T; Hattori N
    PLoS One; 2018; 13(5):e0198039. PubMed ID: 29795667
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke.
    Su EJ; Cao C; Fredriksson L; Nilsson I; Stefanitsch C; Stevenson TK; Zhao J; Ragsdale M; Sun YY; Yepes M; Kuan CY; Eriksson U; Strickland DK; Lawrence DA; Zhang L
    Acta Neuropathol; 2017 Oct; 134(4):585-604. PubMed ID: 28725968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke.
    Shi K; Zou M; Jia DM; Shi S; Yang X; Liu Q; Dong JF; Sheth KN; Wang X; Shi FD
    Circ Res; 2021 Jan; 128(1):62-75. PubMed ID: 33070717
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How can we improve stroke thrombolysis rates? A review of health system factors and approaches associated with thrombolysis administration rates in acute stroke care.
    Paul CL; Ryan A; Rose S; Attia JR; Kerr E; Koller C; Levi CR
    Implement Sci; 2016 Apr; 11():51. PubMed ID: 27059183
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
    Liu W; Hendren J; Qin XJ; Liu KJ
    Stroke; 2009 Jul; 40(7):2526-31. PubMed ID: 19478225
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The iScore predicts efficacy and risk of bleeding in the National Institute of Neurological disorders and Stroke Tissue Plasminogen Activator Stroke Trial.
    Saposnik G; Demchuk A; Tu JV; Johnston SC;
    J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):876-82. PubMed ID: 23102741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-density lipoprotein level is associated with hemorrhage transformation after ischemic stroke treatment with intravenous thrombolysis: A systematic review and meta-analysis.
    Zhang W; Li W; Tian R; Cao L
    J Clin Neurosci; 2022 Dec; 106():122-127. PubMed ID: 36283344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of PI3Kγ by AS605240 plus low-dose tissue plasminogen activator (tPA) combination improves thrombolytic therapy in a rat model of embolic stroke.
    Jin R; Zhong W; Liu S; Wang M; Li G
    Neurosci Lett; 2020 Nov; 738():135339. PubMed ID: 32882317
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke.
    Lapergue B; Dang BQ; Desilles JP; Ortiz-Munoz G; Delbosc S; Loyau S; Louedec L; Couraud PO; Mazighi M; Michel JB; Meilhac O; Amarenco P
    Stroke; 2013 Mar; 44(3):699-707. PubMed ID: 23422087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
    Amlie-Lefond C; Shaw DWW; Cooper A; Wainwright MS; Kirton A; Felling RJ; Abraham MG; Mackay MT; Dowling MM; Torres M; Rivkin MJ; Grabowski EF; Lee S; Kurz JE; McMillan HJ; Barry D; Lee-Eng J; Ichord RN
    Stroke; 2020 Feb; 51(2):542-548. PubMed ID: 31842706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.
    Liang J; Qi Z; Liu W; Wang P; Shi W; Dong W; Ji X; Luo Y; Liu KJ
    Stroke; 2015 May; 46(5):1344-1351. PubMed ID: 25804925
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Platelet-targeted thrombolysis for treatment of acute ischemic stroke.
    Palazzolo JS; Ale A; Ho H; Jagdale S; Broughton BRS; Medcalf RL; Wright DK; Alt K; Hagemeyer CE; Niego B
    Blood Adv; 2023 Feb; 7(4):561-574. PubMed ID: 35482909
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of thrombolysis in telestroke: A systematic review and meta-analysis.
    Kepplinger J; Barlinn K; Deckert S; Scheibe M; Bodechtel U; Schmitt J
    Neurology; 2016 Sep; 87(13):1344-51. PubMed ID: 27566746
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies.
    Tsivgoulis G; Eggers J; Ribo M; Perren F; Saqqur M; Rubiera M; Sergentanis TN; Vadikolias K; Larrue V; Molina CA; Alexandrov AV
    Stroke; 2010 Feb; 41(2):280-7. PubMed ID: 20044531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity.
    Chen QF; Liu YY; Pan CS; Fan JY; Yan L; Hu BH; Chang X; Li Q; Han JY
    Stroke; 2018 Sep; 49(9):2211-2219. PubMed ID: 30354988
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Chinese herbal medicine on poststroke depression in animal models: A systematic review and meta-analysis.
    Li L; Huo B; Wang Y; Wang Y; Gong Y; Zhang Y; Liu T; Sha G; Zheng T
    Front Neurol; 2022; 13():1095444. PubMed ID: 36698870
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual Antiplatelet Therapy Increases Hemorrhagic Transformation Following Thrombolytic Treatment in Experimental Stroke.
    Zheng Y; Lieschke F; Schaefer JH; Wang X; Foerch C; van Leyen K
    Stroke; 2019 Dec; 50(12):3650-3653. PubMed ID: 31587659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.